Story perspectives

Vlasic Labs' CBD Line Approved for Medicare Pilot Program

4/2/2026

Summary

Story summary

Vlasic Labs announced its CBD product line complies with the CMS pilot program, enabling healthcare organizations to provide hemp-derived products to Medicare beneficiaries.
MMJ International Holdings criticized the CMS pilot.
MMJ International Holdings CEO Duane Boise stated that scientific validation must precede reimbursement, warning against treating cannabinoids as commodities.
The CMS pilot's launch coincides with a White House review of FDA enforcement policies.

1 of 1

Story summary

Vlasic Labs announced its CBD product line complies with the CMS pilot program, enabling healthcare organizations to provide hemp-derived products to Medicare beneficiaries.
MMJ International Holdings criticized the CMS pilot.
MMJ International Holdings CEO Duane Boise stated that scientific validation must precede reimbursement, warning against treating cannabinoids as commodities.
The CMS pilot's launch coincides with a White House review of FDA enforcement policies.